Ena Respiratory is a Melbourne-based biotechnology company focused on developing and commercialising drug therapies for respiratory diseases. The company's primary aim is to improve health outcomes and quality of life for people suffering from such diseases, including asthma and chronic obstructive pulmonary disease (COPD). They work closely with leading global researchers and clinicians to create therapies that address unmet medical needs in these areas.

One of Ena Respiratory's key projects is INNA-051, a synthetic small molecule designed to boost the innate immune system in the respiratory tract. The treatment has shown potential to significantly reduce the severity of symptoms and improve recovery times in viral respiratory diseases. Ena Respiratory is committed to conducting rigorous clinical trials to ensure the safety and efficacy of their treatments and to bring these much-needed therapies to patients.

Connect